Key result
Apixaban significantly reduced all-cause hospitalizations compared with enoxaparin/warfarin in patients with acute venous thromboembolism (5.72% vs 7.07%; HR 0.804; 95% CI 0.650-0.995; P=0.045).
RCT (n=5,365)
Hazard Ratio: 0.804 (95% CI 0.65–0.995)
Absolute Event Rate: 5.72% vs 7.07%
p-value: p=0.045
No takes yet. Share an insight, caveat, or question.
Supports apixaban preference in acute VTE to reduce hospitalizations; extends RCT evidence to patient-centered outcomes.
Liu et al. (2015) conducted an RCT in Acute venous thromboembolism (n=5,365). Apixaban vs. Enoxaparin/warfarin was evaluated on All-cause hospitalizations during the treatment period (HR 0.804, 95% CI 0.650-0.995, p=0.045). Apixaban significantly reduced all-cause hospitalizations compared with enoxaparin/warfarin in patients with acute venous thromboembolism (5.72% vs 7.07%; HR 0.804; 95% CI 0.650-0.995; P=0.045).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: